Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayed Start Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients

NCT03935724 is registered in ClinicalTrials.gov with Neuroplast as lead sponsor.

NCT NCT03935724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03935724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Double-blind, Randomized, Placebo-controlled, Delayed Start Phase II/III Study to Assess the Efficacy and Safety of Neuro-Cells in (Sub)Acute Spinal Cord Injury Patients
Lead sponsor
Neuroplast
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 18, 2022
Completion date
August 1, 2024
Enrollment
16 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury, paraplegia, spinal, paraplegia; traumatic, spinal cord injuries